Global X Management Co. LLC Increases Holdings in DexCom, Inc. (DXCM)

Global X Management Co. LLC lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 56.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,063 shares of the medical device company’s stock after purchasing an additional 22,362 shares during the period. Global X Management Co. LLC owned 0.07% of DexCom worth $3,562,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of DXCM. JPMorgan Chase & Co. increased its stake in shares of DexCom by 143.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,358,507 shares of the medical device company’s stock worth $107,170,000 after purchasing an additional 7,738,678 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of DexCom by 29.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock worth $431,510,000 after purchasing an additional 1,991,094 shares in the last quarter. Brown Advisory Inc. increased its stake in shares of DexCom by 57.2% in the 3rd quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after purchasing an additional 1,515,134 shares in the last quarter. Frontier Capital Management Co. LLC increased its stake in shares of DexCom by 85.0% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 848,670 shares of the medical device company’s stock worth $41,521,000 after purchasing an additional 389,947 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of DexCom by 1,190.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 333,978 shares of the medical device company’s stock worth $16,338,000 after purchasing an additional 308,098 shares in the last quarter.

In other DexCom news, CEO Kevin R. Sayer sold 12,000 shares of the stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $55.00, for a total transaction of $660,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Barbara Kahn sold 3,000 shares of the stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $54.58, for a total transaction of $163,740.00. Following the transaction, the director now directly owns 4,353 shares of the company’s stock, valued at approximately $237,586.74. The disclosure for this sale can be found here. Insiders sold a total of 48,140 shares of company stock valued at $2,743,281 in the last ninety days. 1.70% of the stock is currently owned by insiders.

Several research firms have recently commented on DXCM. Zacks Investment Research lowered DexCom from a “hold” rating to a “sell” rating in a research note on Tuesday. Oppenheimer set a $67.00 price objective on DexCom and gave the stock a “buy” rating in a research note on Monday, February 12th. ValuEngine lowered DexCom from a “hold” rating to a “sell” rating in a research note on Thursday, February 8th. BidaskClub lowered DexCom from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 18th. Finally, Northland Securities restated a “sell” rating and issued a $40.00 price objective on shares of DexCom in a research note on Tuesday, January 16th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $67.44.

DexCom, Inc. (NASDAQ:DXCM) opened at $57.34 on Friday. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom, Inc. has a 1-year low of $42.62 and a 1-year high of $86.32.

ILLEGAL ACTIVITY WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/17/global-x-management-co-llc-increases-holdings-in-dexcom-inc-dxcm.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply